If a company partnered with NWBO or a major financing occurred, a seat on the board should certainly be a possibility. If a BP were to take a major partnership position, say 20% of the company, or more, they would almost certainly get multiple seats on the board. Effectively such a partnership would give them a great deal of control, especially as Institutional ownership grows. With the support of Institutional owners a BP that owned 20% of the company couldn't be stopped in an issue it brought to a shareholders vote. I'm fine with partnerships, but I really don't want to see major equity sold until we're selling well into double digit share prices.
I know many believe Merck will at some point be our partner or buyer, if so, I hope it's not until we're selling for $15 or more, so they can justify paying $30 or more for the stock. I would not be surprised with the acceptance of the EDEN unit if some agreement were made with CRL and it could involve a small equity position, say 5% or less, where CRL becomes a major commercial producer of the vaccine as well as taking care of it cryogenic storage and distribution. I would hope that CRL would bring in a billion or more but it wouldn't be just for the stock, it would also be for the rights to lease the EDEN's from the company and producing the vaccine for them. On a share basis this might be in the $30 range, but the shares would be just a part of the deal, so you'd have to consider the price per share being lower, but other things considered in the cost. CRL would make their money back many times over with the sale of vaccine they'd be manufacturing, storing, and distributing.
Gary
Bullish
Market Data 
Markets 
AI
